疾病修饰治疗对镰状细胞贫血患儿左心室舒张功能的纵向影响
该前瞻性研究纳入204例HbSS或HbSβ0-地中海贫血患儿,每2年行超声心动图评估舒张功能,观察羟基脲和每月红细胞输注对舒张功能参数的影响。整个队列左心房容积指数(LAVi)2年内增加3.40±10.86 mL/m2(p=.001),接受疾病修饰治疗者舒张功能未见改善,羟基脲组LAVi增加14%、室间隔e'降低约5%。
要点
- 204例HbSS或HbSβ0-地中海贫血患儿中,112例接受疾病修饰治疗(羟基脲72例、每月红细胞输注40例)。
- 整个队列2年内LAVi增加3.40±10.86 mL/m2(p=.001),该增加与贫血、基线E/e'高或左室扩张独立相关。
- 接受疾病修饰治疗者舒张功能未见改善;羟基脲组LAVi增加14%、室间隔e'降低约5%。
核心结论
- 接受疾病修饰治疗的患儿在研究期间舒张功能未见改善,羟基脲组舒张参数可能恶化。
- 需进一步研究评估更长时间暴露于疾病修饰治疗或达到更高HbF水平是否可能有益于减轻舒张功能障碍。
研究设计与样本
- 前瞻性评估羟基脲和每月红细胞输注对舒张功能参数2年影响的研究。
- 共纳入204例HbSS或HbSβ0-地中海贫血受试者(平均年龄11±3.7岁),未按疾病严重程度筛选。
- 每2年行超声心动图评估舒张功能,共两次。
- 2年观察期间,112例接受疾病修饰治疗(羟基脲n=72,每月红细胞输注n=40),34例开始羟基脲,58例未接受任何疾病修饰治疗。
主要发现
- 整个队列2年内LAVi增加3.40±10.86 mL/m2(p=.001)。
- LAVi增加与贫血、基线E/e'高或左室扩张独立相关。
- 未暴露于疾病修饰治疗者更年轻(平均年龄8.8±2.9岁),但基线舒张参数异常患病率与年龄更大的暴露者(平均年龄12±3.8岁)相似。
- 接受疾病修饰治疗者研究期间舒张功能未见改善。
- 羟基脲组LAVi增加14%、室间隔e'降低约5%,胎儿血红蛋白(HbF)水平降低约9%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 需进一步研究评估更长时间暴露于疾病修饰治疗或达到更高HbF水平是否可能有益于减轻舒张功能障碍。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Cardiac abnormalities seen in sickle cell anemia (SCA) include diastolic dysfunction, which has been shown to be associated with high morbidity and early mortality. The effect of disease-modifying therapies (DMT) on diastolic dysfunction is poorly understood. We prospectively evaluated the effects of hydroxyurea and monthly erythrocyte transfusions on diastolic function parameters over 2 years. A total of 204 subjects with HbSS or HbSβ0-thalassemia (mean age 11 ± 3.7 years), unselected for disease severity, had diastolic function assessed with surveillance echocardiograms twice, 2 years apart. During this 2-year observation period, 112 participants received DMTs (hydroxyurea, n = 72, monthly erythrocyte transfusions, n = 40), 34 initiated hydroxyurea, and 58 did not receive any DMT. The entire cohort showed an increase in left atrial volume index (LAVi) of 3.40 ± 10.86 mL/m2, p = .001 over 2 years. This increase in LAVi was independently associated with anemia, high baseline E/e' or LV dilation. Individuals not exposed to DMT were younger (mean age 8.8 ± 2.9 years), but at baseline their prevalence of abnormal diastolic parameters was similar to that of the DMT-exposed participants who were older (mean age 12 ± 3.8 years). Participants on DMTs saw no improvement in diastolic function over the study period. In fact, participants on hydroxyurea saw a possible worsening in diastolic parameters (14% increase in LAVi and ~5% decrease in septal e') but also a ~9% decrease in fetal hemoglobin (HbF) levels. Further studies are needed to evaluate if exposure to DMT for a longer duration or achieving higher HbF might be beneficial in alleviating diastolic dysfunction.
引用
- Rai P, Okhomina VI, Kang G, et al. Longitudinal effect of disease-modifying therapy on left ventricular diastolic function in children with sickle cell anemia. Am J Hematol. 2023. PMID: 36890729. doi:10.1002/ajh.26911
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。